Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Medpace Holdings (MEDP)
NASDAQ:MEDP
Holding MEDP?
Track your performance easily
Earnings Data
Report Date
Feb 17, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
$2.94Last Year’s EPS
$2.46Same Quarter Last Year
Moderate Buy
Based on 7 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Oct 21, 2024
|% Change Since: -4.43%
|Next Earnings Date:Feb 17, 2025
Earnings Call Sentiment|Neutral
The earnings call reflects a mixed performance. While there is strong revenue growth, improved EBITDA margins, and increased cash flow, the company is experiencing challenges with elevated backlog cancellations, decreased net new business awards, and a decline in RFPs. The sentiment is balanced with significant positives but also notable negatives.Company Guidance
During Medpace's Q3 2024 earnings call, executives highlighted several key metrics and guidance. The company reported a 1.0 net book-to-bill ratio for the quarter, with revenue reaching $533.3 million, marking an 8.3% increase year-over-year. The ending backlog stood at approximately $2.9 billion, up 8.8% from the previous year, with expectations for $1.62 billion to convert to revenue over the next 12 months. EBITDA for the quarter was $118.8 million, a 31.7% increase compared to the same period in 2023, resulting in an EBITDA margin of 22.3%. Full-year 2024 revenue is projected between $2.09 billion and $2.13 billion, with EBITDA anticipated to range from $450 million to $470 million. The company expects net income between $376 million and $388 million for the year, with an effective tax rate of 15.5% to 16.5%. Furthermore, Medpace aims for a net book-to-bill ratio greater than 1.15 by the second half of 2025, assuming a return to normal cancellation rates and a stable business environment.Revenue Growth
Revenue for the third quarter of 2024 was $533.3 million, representing a year-over-year increase of 8.3%.
Backlog Increase
Ending backlog as of September 30, 2024, was approximately $2.9 billion, an increase of 8.8% from the prior year.
EBITDA and Margin Improvement
EBITDA of $118.8 million increased 31.7% compared to $90.2 million in the third quarter of 2023. EBITDA margin for the third quarter was 22.3% compared to 18.3% in the prior year period.
Net Income Increase
Net income of $96.4 million increased 36.7% compared to net income of $70.6 million in the prior year period.
Strong Cash Flow
Generated $149.1 million in cash flow from operating activities in the third quarter.
---
MEDP Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
MEDP Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Oct 21, 2024 | $352.92 | $326.54 | -7.47% |
| Jul 22, 2024 | $437.18 | $357.30 | -18.27% |
| Apr 22, 2024 | $376.26 | $407.15 | +8.21% |
| Feb 12, 2024 | $324.21 | $364.10 | +12.30% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Medpace Holdings (MEDP) report earnings?
Medpace Holdings (MEDP) is schdueled to report earning on Feb 17, 2025, TBA Not Confirmed.
What is Medpace Holdings (MEDP) earnings time?
Medpace Holdings (MEDP) earnings time is at Feb 17, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is MEDP EPS forecast?
MEDP EPS forecast for the fiscal quarter 2024 (Q4) is $2.94.
---